Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc became the second U.S company to release full results from a large study of its experimental vaccine, saying it was 94.1% effective against COVID-19.

Factbox: Moderna's mRNA coronavirus vaccine

Moderna Inc. is moving closer to having its COVID-19 vaccine candidate available for distribution, as the biotechnology company said Monday it plans to request an Emergency Use Authorization (EUA) "today" from the U.S. Food and Drug Administration.

Moderna to file for emergency approval of COVID-19 vaccine candidate

The drug company reports that its vaccine is 94.1% effective against COVID-19.

Moderna seeks FDA emergency approval for coronavirus vaccine

Drugmaker Moderna has completed its initial efficacy analysis of its COVID-19 vaccine from the drug's Phase 3 clinical study, and determined that it was 94.1% effective in preventing people from contracting COVID-19 across 196 confirmed cases from among 30,000 participants in the study. Moderna also found that it was 100% effective in preventing severe cases […]

Moderna claims 94% efficacy for COVID-19 vaccine, will ask FDA for emergency use authorization today

Moderna said it will ask the feds to clear its experimental coronavirus vaccine for emergency use on Monday, adding to hopes that two inoculations could be available by the end of the year. The biotech firm will be the second drugmaker to seek a so-called emergency use authorization for a COVID-19 vaccine from the US.

Moderna to ask FDA for emergency clearance of COVID-19 vaccine

Shares in US drugmaker Moderna rose as much as 11% in pre-market trading on Monday after the company filed for US regulatory approval for its COVID-19 vaccine candidate and as final data showed the shot was 94% effective. More to come.

Moderna jumps 11% after filing for FDA approval as final results show its COVID-19 vaccine candidate is 94% effective

Moderna has said it is filing for regulatory approval in the US, and that its vaccine trials have shown no serious safety concerns.

Moderna seeks US approval for 94.1% effective vaccine

Moderna Inc. said Monday that it will file for emergency use authorization from the Food and Drug Administration for its COVID-19 vaccine candidate, mRNA-1273. The biotechnology company also said that the primary analysis of its Phase 3 study of mRNA-1273, conducted on 196 cases, demonstrated an efficacy of 94.1%, which compares with the first interim analysis with a total of 95 cases which demonstrated efficacy of 94.5%.

Moderna to file EUA for COVID-19 vaccine candidate, which showed 94.1% efficacy

Moderna is asking the Food and Drug Administration for emergency approval of its coronavirus vaccine, the Cambridge, Mass.-based biotech firm announced Monday.

Moderna to request emergency authorization of coronavirus vaccine

US company submits data to start approval process with regulators around the world

Moderna Covid vaccine has 94% efficacy, final results confirm

Moderna said it will request emergency clearance from the FDA for its coronavirus vaccine after new data confirms the vaccine is more than 94% effective in preventing Covid-19 and was safe.

Moderna says new data shows Covid vaccine is more than 94% effective, plans to ask FDA for emergency clearance later Monday

If approved, this would mark the first time Moderna has successfully brought a vaccine to market.

Moderna Submits Covid-19 Vaccine For Emergency Approval, Says It Is 100% Effective At Preventing Severe Forms Of Disease

Moderna is set to ask US regulators to allow the emergency use of its experimental coronavirus vaccine, starting a process that could allow the shot to be given more widely within weeks. The biotech company plans to file today for emergency use authorization with the US Food and Drug Administration, Moderna said in a statement, about a week after Pfizer and BioNTech asked the FDA to green light their vaccine. The company is also seeking approval from regulators in other countries.

Moderna is set to ask the FDA to authorize its coronavirus vaccine, a key step before it can be given to more people

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces primary efficacy analysis in Phase 3 COVE study for Its COVID-19 vaccine candidate.

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

BioNTech SE

Pfizer

The U.K. has secured two million more doses of COVID-19 vaccine from Moderna Inc (NASDAQ: MRNA) and is expected to approve the vaccine made by Pfizer Inc (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) this week. What Happened: Moderna is to provide another two million vaccines to the U.K., in addition to a previous 5 million doses, Reuters has reported.

UK To Approve Pfizer-BioNTech Vaccine 'Within Days,' Secures 2M More Doses From Moderna

AstraZeneca

They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces amendment to current supply agreement with United Kingdom government for an additional 2 million doses of mRNA-1273.

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

The UK government on Sunday said it had secured another 2 million doses of Moderna's COVID-19 vaccine, bringing total doses promised to the government to 357 million. "With a wide range of vaccine candidates in our portfolio, we stand ready to deploy a vaccine should they receive approval from our medicines regulator, starting with those who will benefit most," said the health and social care secretary, Matt Hancock, in a government press release. 

UK adds 2 million doses of Moderna's COVID-19 vaccine, upping stockpile to 357 million doses

Novavax

Vaxart

Here's what makes these coronavirus-focused biotechs stand out.

3 COVID Vaccine Stocks That Could Be Millionaire-Makers

The government has secured an additional two million doses of the Moderna COVID-19 vaccine, which trials suggest has a 95% effectiveness.

Two million more Moderna jabs secured as new vaccine minister appointed

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at upcoming investor conferences in December 2020.

Moderna to Present at Upcoming Investor Conferences in December 2020

Sorrento Therapeutics Inc

The Nasdaq Composite pushed further into all-time high territory Friday morning.

These 3 Coronavirus Vaccine Stocks Are Lifting the Nasdaq to New Records

AstraZeneca's slip is sending these two biotechs higher today.

Why Moderna and Novavax Shares Are Racing Higher Today

Moderna (MRNA) signs a deal to supply up to 160 million vaccine doses to European Commission The vaccine is under review in Europe.

Moderna (MRNA) Inks Europe Supply Deal for COVID-19 Vaccine

Its coronavirus vaccine will likely be successful; its technology has huge potential; and the company has a healthy balance sheet.

News for Moderna Stock (MRNA)